Clinical Trials
2 trialsNCT06301438 2026-02-03
Dalpiciclib in HR+/HER2- ABC
RenJi Hospital
Recruiting
NCT05431504 2022-06-24
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting